Cagrilintide 10mg Peptide
Research Use Only
Get Notified When Available
This product is currently out of stock. Enter your email and we'll notify you the moment it's back.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Research Use Only
For in vitro laboratory research by qualified professionals only. Not for human or animal administration. Not intended to treat, prevent, mitigate, or cure any disease. Batch-specific Certificates of Analysis available for all products.
Native amylin is co-secreted with insulin and signals meal termination, but it aggregates readily and clears quickly, which is why analogue design has focused on solubility and half-life. Cagrilintide addresses both through acylation, giving a duration suitable for weekly administration in published protocols. Its dual amylin and calcitonin receptor activity distinguishes it from selective agonists such as eloralintide, and comparing the two is a common experimental design. This 10mg vial supports receptor-binding assays and combination work alongside GLP-1 agonists.
Frequently Bought Together
Cagrilintide 10mg
10mg
$89 USD
Bundle & Save
$189 USD
Save $9 USD
$254 USD
Save $24 USD
$299 USD
Save $44 USD
$399 USD
Save $79 USD
Click any product above to toggle selection
Related Peptides
Related Research News
Cagrilintide Research: What Is Cagrilintide and How Does It Work?
Research review of Cagrilintide, a dual amylin and calcitonin receptor agonist, covering mechanism, preclinical data, and safety.
Cagrilintide-Semaglutide May Aid Type 2 Diabetes Glycemic Control
A combination of cagrilintide and semaglutide could improve glycemic control in patients with type 2 diabetes who are already using basal insulin, according to a report from Docwire News. The finding suggests a potential new treatment option for managing blood sugar levels in this patient population.
Semaglutide Conference Presentation Preview: ObesityWeek 2026
ObesityWeek 2026 is set to feature key semaglutide conference presentations alongside emerging peptide therapeutics. Early reports suggest data on tirzepatide, retatrutide, survodutide, and cagrilintide will be shared, offering researchers a comprehensive look at the evolving obesity treatment landscape.